ReviewPediatric nephrology (Berlin, Germany)2015
Fertility preservation in patients receiving cyclophosphamide therapy for renal disease.
Review in Pediatric nephrology (Berlin, Germany), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 62 citations in OpenAlex.
- Chemotherapy-Induced Infertility: Mechanisms, Risk Factors, and Fertility Preservation Strategies in Cancer Patients.JBRA assisted reproduction · 2026Review
- In Vitro Fertilization is Essential Healthcare for Patients With Rheumatic Disease.ACR open rheumatology · 2026Review
- An updated look into reactive oxygen species and cyclophosphamide-induced ovarian damage.Journal of ovarian research · 2025Review
- Article
- The Oxidative Stress of Human Sperm Cryopreservation.Antioxidants (Basel, Switzerland) · 2025Review
- Cyclophosphamide treatment with a comparison in both pediatric rheumatology and pediatric nephrology practices.Pediatric rheumatology online journal · 2025Article
- Kidney disease and reproductive health.Nature reviews. Nephrology · 2025Review
- Outcome of rituximab treatment in children with non-dialysis-dependent anti-GBM disease.Pediatric nephrology (Berlin, Germany) · 2025Article
- Azilsartan as a preventive agent against cyclophosphamide-induced testicular injury in male rats.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Granulomatosis With Polyangiitis in an Autistic Patient With Depression: Challenges in Diagnosis and Management.Cureus · 2024Article
- Do we really need cyclophosphamide for lupus nephritis?Pediatric nephrology (Berlin, Germany) · 2024Article
- Protective effects of Withania somnifera against cyclophosphamide-induced testicular damage in rats.Clinical and experimental reproductive medicine · 2024Article
- Early-onset lupus nephritis.Clinical kidney journal · 2024Review
- Role of topical and systemic immunosuppression in aqueous-deficient dry eye disease.Indian journal of ophthalmology · 2023Review
- Working Towards a Treat-to-Target Protocol in Juvenile Proliferative Lupus Nephritis - A Survey of Pediatric Rheumatologists and Nephrologists in Germany and Austria.Frontiers in pediatrics · 2022Article
- Phycobiliproteins Ameliorate Gonadal Toxicity in Male Mice Treated with Cyclophosphamide.Nutrients · 2021Article
- Ovarian stimulation is a safe and effective fertility preservation option in the adolescent and young adult population.Journal of assisted reproduction and genetics · 2020Article
- Development of a Pediatric Fertility Preservation Program: A Report From the Pediatric Initiative Network of the Oncofertility Consortium.The Journal of adolescent health : official publication of the Society for Adolescent Medicine · 2019Review
- Cerium Oxide Nanoparticles Protect Cyclophosphamide-induced Testicular Toxicity in Mice.International journal of preventive medicine · 2019Article
- Process and Pitfalls of Sperm Cryopreservation.Journal of clinical medicine · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cyclophosphamide continues to have an important role in the treatment of renal disease, including nephrotic syndrome and lupus nephritis, despite known complications of gonadotoxicity and potential infertility in both male and female patients. It is important that the physician recommending this therapy mitigates the effect of the drug on fertility by adhering to recommendations on dosing limits and offering fertility-preserving strategies. In addition to well-established methods, such as sperm banking and embryo cryopreservation, advances in reproductive technology have yielded strategies such as oocyte cryopreservation, resulting in more fertility-preserving options for the pediatric patient. Despite these advances, there continues to be a significant barrier to referral and access to sperm banks and fertility specialists. These issues are further complicated by ethical issues associated with the treatment of pediatric patients. In this review we explore the development of recommended dosing limits and include a discussion of the available fertility-preserving methods, strategies for increasing access to fertility specialists, and the ethical considerations facing the pediatric healthcare provider.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.